No Picture
Newsmakers

Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the […]

No Picture
Newsmakers

BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025  — BioXcel Therapeutics, […]

Newsmakers

PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively – – FREEDOM-DM1 15 […]

No Picture
Newsmakers

ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas

ScanTech AI is leading the charge in combating contraband in correctional facilities with cutting-edge artificial intelligence merged with advanced CT scanning technology Atlanta, GA, Feb. 18, 2025 — ScanTech AI Systems Inc. (NASDAQ: STAI) (“ScanTech […]

No Picture
Newsmakers

ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

GARDEN CITY, NY, Feb. 18, 2025  — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, […]

Newsmakers

Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

NASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. […]

Newsmakers

Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

SRC recommended that the trial escalate to the next dose level of 22mg capsule No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 — Pasithea […]

Newsmakers

BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG)

MCLEAN, Va., January 30, 2025—-BigBear.ai (NYSE: BBAI), a leader in AI-powered decision intelligence for defense and national security, has been awarded a prime Indefinite Delivery/Indefinite Quantity (IDIQ) contract under the U.S. Department of Navy’s SeaPort […]

No Picture
Newsmakers

ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation

Buford, GA, Jan. 30, 2025– ScanTech AI Systems, Inc. (NASDAQ: STAI, ScanTech, or ScanTech AI), a security solutions provider offering one of the world’s most advanced non-intrusive “fixed-gantry” CT screening technologies, proudly announced today the […]

Newsmakers

Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

SYDNEY, Jan. 30, 2025  — Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in […]

No Picture
Newsmakers

NEWTON GOLF Company (NASDAQ: SPGC) Provides Preliminary Financial Results for Fourth Quarter 2024 and Full Year 2024

CAMARILLO, CA, Jan. 27, 2025 — NEWTON GOLF Company (NASDAQ: SPGC) (“NEWTON GOLF” or the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other […]

No Picture
Newsmakers

NanoVibronix (NASDAQ: NAOV)Advances Development of PainShield and UroShield with Completion of NextGen Prototypes

Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing ELMSFORD, N.Y., January 07, 2025—-NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, […]

No Picture
Newsmakers

Nvni Group Limited (NASDAQ: NVNI) reports 2023 FY results: Net Revenue growth of 36%, Adjusted EBITDA up 142% Nvni Group Limited December 26, 2024 5 min read

NEW YORK, Dec. 26, 2024 — Nvni Group Limited (NASDAQ: NVNI) (“Nuvini” or the “Company”), the leading serial acquirer of private SaaS B2B companies in Latin America reports financial results for FY 2023: Key highlights: […]

Newsmakers

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., (NASDAQ: ELAB) to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by […]